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Increased production of interleukin-2 and IL-2 receptor in primary IgA
nephropathy. The production of interleukin-2 (IL-2) by peripheral blood
mononuclear cells (PB MC) in 13 patients with IgA nephropathy (IgAN)
and 9 patients with chronic glomerulonephritis was investigated. More-
over, the distribution of IL-2 receptor (IL-2R) expression was studied in
the purified T cell population versus the non-T cell population of IgAN
patients. The results show a spontaneous significant production of IL-2
in cultures of PBMC from patients with IgAN (P < 0.025) that increased
after PHA stimulation. IgAN patients also had a significantly higher
expression of IL-2R on the surface of PBMC than did patients with
chronic glomerulonephritis (P < 0.05). IL-2R was usually detected on
unstimulated purified T cells that expressed the activation DR antigen.
Moreover, a high number of DR helper T cells was associated to a
reduced number of suppressor T cells (OKT8M1). These findings
suggest that the increased production of IL-2 in patients with IgAN may
be responsible for the increased activity of helper T cells. The high
number of IL-2R expressed by freshly separated PBMC implies an in
vivo continuous stimulation of these cells, and this finding is in
agreement with the demonstrated spontaneous hyperproduction of
IL-2. Moreover, the low number of suppressor T cells may contribute
to the overactivity of helper T cells bearing IL-2R in IgAN patients.
Interleukin-2 (IL-2), produced by stimulated T cells, is a
polypeptide hormone with an approximate molecular weight of
15,000 daltons. It plays an important role in the induction of T
cell-mediated immunity. IL-2 acts as a T cell growth factor [1],
stimulates immunoglobulin response to cell-dependent antigens
and mitogens [2], and promotes and maintains the proliferation
of cytotoxic and suppressor T cells [3]. Although the T cell
subset responsible for IL-2 production has not been well
defined, many investigators [4, 5] have reported that both
OKT4 and OKT8 cell subclasses are able to produce IL-2. Its
activity is mediated by binding to specific T cell surface
receptors (IL-2R, TAC antigen) requiring the accessory func-
tion of macrophage and/or IL-l produced by macrophages [6,
7].
The relationship between IL-2 production and T cell-medi-
ated immunity has been investigated in many diseases such as
sarcoidosis [8], diabetes mellitus [9], systemic lupus erythema-
tosus [10, 11], and the acquired immunodeficiency syndrome
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[12, 13], in which a defect in the production of and responsive-
ness to IL-2 was observed.
Idiopathic glomerulonephritis with mesangial deposits of IgA
(IgAN) is characterized by the presence in the blood of in-
creased IgA-specific helper T cell activity with the receptor for
the Fe portion of IgA (Ta cells) [14], decreased IgA-specific
suppressor T cell activity [15] and increased number of periph-
eral B lymphocytes with !gA Fe receptors (Ba cells) [16].
On the basis of the above immunological dysfunctions, we
have investigated the production of IL-2 from peripheral blood
mononuclear cells (PBMC) of patients with both active and
inactive IgAN. The distribution of IL-2R was also studied on
PBMC surface.
Methods
Patients
The study was carried out in 13 patients with IgAN, in 9
patients with chronic glomerulonephritis (membranous GN 3
cases, membranoproliferative GN 2, mesangial proliferative
GN 4 cases) and in 7 healthy volunteers matched for age and
sex. Patients with chronic GN are designated non-IgAN. The
age of the patients ranged from 22 to 67 years. Neither patients
nor controls had taken steroids or immunosuppressive drugs
prior to the study.
Peripheral blood mononuclear cell (PBMC) isolation
Mononuclear cells were isolated from heparinized peripheral
blood by Böyum's method [17]. The cell suspension recovered
at the interface was resuspended in RPMI 1640 (Eurobio, Paris,
France) and supplemented with penicillin (100 lU/mi) strepto-
mycin (100 sg/ml), glutamine (2 mM) and 10% heat-inactivated
fetal calf serum (FCS; complete medium).
Purification of T and non-T cell population
Fractions enriched for T cells were obtained by rosette
formation with neuraminidase-treated sheep red blood cells
(SRBC). E-rosette forming (T cells) and non-rosetting cells
(non-T cells) were separated by lymphoprep density gradient
centrifugation. The purified T cells (approximately 90% E cells)
were obtained after hypotonic lysis of SRBC and were washed
for use in the assay. The non-T cell fraction consisted of 70 to
85% B cells (sIg) with 13 to 25% monocytes, and served as
source of B cells.
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Enriched OKT4 and OKT8 lymphocyte subpopulations
Purified T cells were depleted of OKT4 or OKT8 cells by
complement-mediated cytolysis {1]. Briefly, cell suspensions
(2 x 10) were incubated with OKT4 or OKT8 monocional
antibodies (1:200 dilution; Ortho Diagnostic System, Milan,
Italy) and 2 ml of RPMI 1640 containing 2.5% FCS for 10
minutes at 37°C, followed by incubation for 50 minutes at 4°C.
After centrifugation (3000 g for 10 mm), rabbit complement
diluted (1: 10) in RPM! 1640 supplemented with 2.5% FCS was
added to each cell suspension. Following incubation for one
hour at 37°C, cells were washed and this treatment was re-
peated. OKT4 or OKT8 enriched cell suspensions contained
less than 9% 0KT8 cells or less than 7% 0KT4 cells,
respectively, as determined by immunofluorescence using flu-
orescein isothiocyanate (FITC) conjugated OKT8 or OKT4
monoclonal antibodies (Ortho Diagnostic).
OKDR AND OKT8 M1 surface phenotypes
OKDR cell subpopulation was detected using OKDR mono-
clonal antibody (Techno Genetics, Milan, Italy) in purified T
cell population. 0KT8M1 cells were detected using 0KM!
monoclonal antibody (Ortho Diagnostic) in an 0KT8 enriched
cell subpopulation.
IL-2 production
PBMC at a concentration of 2 x 106 cells/rn! were stimulated
with phytohemaglutinin (PHA), 5 pg/rnl for 24 hours at 37°C in
a 5% C02-95% air atmosphere. At the end of this period,
cell-free supernatant was obtained by centrifugation at 2000
rpm for 10 minutes and frozen at —70°C until used to detect and
quantify IL-2.
Human IL-2 ELISA
The technique was carried out by a commercially-available
enzyme immunoassay kit (Inter-test 2, Genzyrne, Boston, Mas-
sachusetts, USA) based on the "dual antibody immunornetric
sandwich" principle. A polystyrene immunoplate was coated
with mouse monoclonal anti-IL-2 antibody specific for IL-2 and
the wells were incubated with the test samples and appropriate
standards. The rabbit po!yva!ent antibody to human IL-2 was
then incubated in the wells, after which a third enzyme-labelled
goat anti-rabbit antibody (conjugated with alkaline phospha-
tase) was incubated in the wells. The bound, specific anti-IL-2
antibody was quantified by an enzymatic reaction resulting in a
detectable color change using an automatic plate reader (Ti-
tertek Multiskan Plus, Flow Labs, USA) with a 405 nm filter. A
standard curve was obtained by plotting the IL-2 concentration
of the standards against absorbance. The standards were pre-
pared by reconstitution of the !yophilized rIL-2 just prior to use
with 1.0 ml of the provided diluent. The appropriate standards
contained 50 U/rn!, 5 U/mI, 0.50 U/ml and 0.05 U/rn! of IL-2,
respectively. The IL-2 concentration of the unknown samples
was determined by comparison with the standard curve and
expressed as units of IL-2/ml (U/mi).
Analysis of IL-2R on the PBMC with monoclonal antibody
For this purpose a monoc!onal antibody (IgG 1) to TAC was
purchased from Techno Genetics; 10 pA of this antiserum were
incubated with a 50 pA suspension of 1 x 106 pelleted cells for 30
Fig. 1. Spontaneous (A) and PHA-induced (B) IL-2 production in
cultures of PBMC from 7 healthy subjects (EJ), 13 patients with IgAN(L:) and 9 patients with chronic glomerulonephritis (). The va!ues
are expressed as mean SEM.
minutes at 4°C. After two washes with cold phosphate-buffered
saline the cel!s were resuspended in 10 pA, FITC goat anti-
mouse Ig F(ab')2 (Techno Genetics) at 4°C for 30 minutes,
washed again and read on an Olympus BH-2 microscope
equipped for epifluorescence.
Statistical analysis
The values from the group of patients have been expressed as
the mean SEM. Group means were compared using the
Student's t-test and the Mann-Whitney U-test.
Results
In preliminary PHA titrations it was found that as little as 5
g/ml of PHA was sufficient to maximally stimulate IL-2
production from PBMC in healthy subjects. Therefore, this
amount of mitogen has been used throughout the study.
The results, summarized in Figure 1, show that a significant
spontaneous IL-2 production was generated in cultures of
PBMC from patients with IgAN (P <0.025). By contrast, no
significant IL-2 production was observed in cultures of PBMC
from non-IgAN patients or from healthy subjects. Increased
production of IL-2 was observed in healthy subjects (P <
0.005), and patients with IgAN (P <0.005) and subjects with
CGN (P < 0.05) after PHA stimulation. However, IL-2 produc-
tion was more significantly increased in IgAN patients (P <
0.005). The highest IL-2 values were found in two patients who
had serum creatinine leve!s greater than 2 mg/dl (data not
shown).
In light of these findings, it was of interest to evaluate
spontaneous production of IL-2 in three patients during the
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Fig. 2. !L-2 production in cultures of PBMC from three patients with
IgAN during and after the acute phase of the disease (infection of the
upper respiratory tract, fever and macrohematuria). The values are
expressed as mean SEM, (A) spontaneous IL-2 production, (B)
PHA -induced IL-2 production, (C) serum creatinine.
acute phase of the disease. Figure 2 illustrates spontaneous IL-2
secretion as a mean SEM. Such a release decreased greatly
during the follow-up but remained in the upper limits of the
normal range (Fig. 2A). The same behavior was seen in cultures
of IgAN PBMC from the same subjects stimulated with PHA,
although the production of IL-2 was higher than that observed
in unstimulated PBMC (Fig. 2B). Serum creatinine, which was
slightly increased during the macrohematuria episode, de-
creased in the weeks that followed (Fig. 2C).
In order to verify the possibility that higher IL-2 activity in
IgAN may be due to a reduced shedding of IL-2 by the activated
T cells, the distribution of IL-2R in PBMC was examined in 8
patients. Figure 3 shows that the IgAN patients had signifi-
cantly higher expression of IL-2R on the surface of PBMC than
No. of cases
Fig. 3. IL-2R expression on the surface of PBMC (A) and on PHA-
stimulated PBMC (B) from healthy subjects (El), patients with IgAN(iII) and those with chronic glomerulonephritis (ll). The values are
expressed as mean SEM.
0
Fig. 4. Percentage of(A) TAC cells in PBMC and in the purified T cell
population from patients with IgAN. (B) Purified T cells reveal a higher
percentage of OKDR cells in IgAN patients. The values are expressed
as mean SEM.
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did the healthy subjects (P < 0.001). A significant increase of
IL-2R expression was observed on the surface of PBMC from
patients with IgAN after PHA stimulation (P < 0.001) and
patients with non-IgAN (P < 0.025).
To investigate the TAC cell distribution we separated T
cells from non-T cells in 4 patients with IgAN by the E-rosette
technique. A higher significant percentage of TAC + cells was
detected in PBMC (P < 0.01) and in the purified T cell
population (P <0.005) in comparison with similar cell suspen-
sion from healthy blood donors (Fig. 4). On the contrary no
TAC cells were detected in the non-rosetting fraction. More-
over, purified T cells revealed a more elevated percentage of
OKDR cells (P < 0.005) with respect to normal controls, this
supporting the presence of in vivo activated T cells (Fig. 4).
Since it is well known that OKT8 cells exerting suppressor
function of B cell activity bear Ml antigen, the frequency of
OKT8Ml cells was evaluated in enriched T8 cells from
both IgAN patients and healthy subjects. Results provide
B
I— 0.001 —I
I— 0.025 -4
nih
•555
....S...
I— 0.001 —I
a -z-6-
4-
2
0 1
6 8 6 6 8 6
878 Schena et al: Interleukin-2 and IL-2 receptor in primary IgAN
evidence that a lower significant percentage of OKT8Ml +
cells was found in the purified T8 cell population from IgAN
patients when compared to controls (P < 0.025; Fig. 5).
Discussion
The results of the present study indicate that a spontaneous
production of IL-2 by PBMC occurs in patients with primary
IgAN. Mitogen-stimulated PBMC produce larger amounts of
IL-2 and these levels contrast with normal values observed in
PBMC from patients with chronic non-IgAN. Moreover, a
significant increase of IL-2R expression was found on PBMC
from IgAN patients in resting conditions and after PHA stimu-
lation.
IgAN is characterized by an increased number of Ta cells in
the blood [14]. This T cell subset is characterized by the Fc
receptor for IgA and by the helper activity in PWM-induced B
cell differentiation system, especially for IgA-producing cells
(Ba cells) [161. Some investigators [19] have suggested that the
increased activity of helper T cells in IgA synthesis might be the
primary defect in IgAN. In this framework, it is conceivable
that the spontaneous IL-2 hyperproduction seen in patients
considered in this study may be the cause of the observed
increased activity of helper T cells. In fact, IL-2 is a polypeptide
hormone produced by T cells, and is critically involved both
during the initial stage of T cell-dependent B cell activation and
in the final stage of B cell differentiation [2].
Consequently, a spontaneous hyperproduction of IL-2 may
play a critical role in the higher IgA synthesis in patients with
IgAN during the remission phase of the disease, as also
supported by Ig production in a spontaneous plaque-forming
cell system [201.
First reports [21, 22] on the detection of IL-2R by monoclonal
antibody (anti-TAC) indicated that IL-2R is expressed by
activated human T cells but not by fresh peripheral blood T
cells, B cells, monocytes, thymocytes and B cells activated by
different antigens. The demonstration that an increased number
of IL-2R is expressed by freshly separated PBMC, preferen-
tially T cells, in patients with IgAN suggests that a continuous
stimulation is present in these patients which is in agreement
with the demonstrated spontaneous hyperproduction of IL-2. In
fact, it may be expected that IL-2R is expressed on T cells not
only after in vitro activation but also after in vivo activation by
specific antigen.
To further investigate this point we have evaluated the
expression of another activation antigen such as DR on unstim-
ulated purified T cells from IgAN patients. The increased
OKDR cell frequency observed in these subjects fully sup-
ports this hypothesis.
Since the production of IL-2 may be related to the hyperac-
tivity of helper T cells as a consequence of an imbalance of T
helper/T suppressor ratio we studied the number of suppressor
T cells. It is well known that suppressor T cells (that is,
OKT8) can be divided into two different subsets according to
Ml antigen expression [23, 24]. The suppressor activity on B
cell function is confined to the subset expressing Ml antigen
(that is, OKMl). Therefore, we have studied the OKT8Ml
cell frequency in purified T cell population from IgAN patients.
Our data support the hypothesis that the oversynthesis of Ig
may be explained by the overactivity of helper T cells since the
number of these suppressor T cells (OKT8Ml) is signifi-
cantly reduced in IgAN.
Altogether, these results indicate that the higher spontaneous
IL-2 synthesis, due to in vivo activation, may play a key role in
the pathogenesis of IgAN. Considering the presence of sponta-
neous IL-2 production in patients with IgAN, a putative rapid
acquisition of IL-2R by the T cell population might explain the
continuous production or increased production of polymeric
IgA in these patients [25].
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